Skip to main content

Table 3 Characteristics of patients with and without acute biliary events

From: Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study

  ABE group (n = 195) Non-ABE group (n = 159,371)
Age (years)a* 66.2 ± 13.5 56.6 ± 19.7
Maleb 132 (67.7) 109,399 (68.6)
Tuberculosis diagnostic yearb
 1996–2000 60 (30.8) 48,844 (30.6)
 2001–2005 73 (37.4) 59,424 (37.3)
 2006–2010 62 (31.8) 51,103 (32.1)
Co-morbidity (%)
 Diabetes mellitusb* 63 (37.4) 38,075 (23.9)
 Chronic obstructive pulmonary diseaseb 10 (5.1) 7918 (5.0)
 Malignancyb 12 (6.2) 6712 (4.2)
 End-stage renal diseasec 2 (1.0) 1998 (1.3)
 Connective tissue diseasec 0 (0.0) 1151 (0.7)
 Acquired immunodeficiency syndromec 1 (0.5) 562 (0.4)
 Liver cirrhosisc 1 (0.5) 323 (0.2)
 Transplantationc* 1 (0.5) 137 (0.1)
 Pneumoconiosisc 0 (0) 85 (0.1)
Low incomeb 5 (2.6) 4830 (3.0)
Total duration of anti-TB treatment 266.9 ± 99.7 260.4 ± 105.8
 Intensive phase (initial 60 days)a
  No. of days covered by isoniazida 47.7 ± 18.6 50.0 ± 11.2
  No. of days covered by rifamycina* 48.9 ± 13.4 51.7 ± 11.2
  No. of days covered by ethambutola 51.2 ± 11.4 50.8 ± 13.1
  No. of days covered by pyrazinamidea 39.9 ± 21.3 42.5 ± 20.4
 Initial 180 days
  No. of days covered by isoniazida* 134.4 ± 52.2 142.4 ± 53.4
  No. of days covered by rifamycina* 140.1 ± 37.9 152.5 ± 32.8
  No. of days covered by ethambutola 145.2 ± 35.6 141.9 ± 42.2
  No. of days covered by pyrazinamidea 67.8 ± 44.9 69.3 ± 45.8
  1. Data are presented as number (%) or mean ± standard deviation
  2. aCompared using an independent-sample t test
  3. bCompared using a chi-square test
  4. cCompared using a Fisher exact test
  5. *p < 0.05 for the comparison between the ABE and non-ABE groups